Clinical Trial

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-05-08; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2023-12-13
Trial Details
NCT Number NCT05860465
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Locally Advanced or Metastatic Breast Cancer
Enrollment 254 participants
Start Date 2023-09-08
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-14